about
Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells.Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.Safety of biologics in psoriasis.Evaluation of IgG4+ Plasma Cell Infiltration in Patients with Systemic Plasmacytosis and Other Plasma Cell-infiltrating Skin Diseases.Open-label pilot study to evaluate the effectiveness of topical bimatoprost on rhododendrol-induced refractory leukoderma.Cutaneous sarcoidosis in a patient with rheumatoid arthritis receiving tocilizumabLinear immunoglobulin A bullous dermatosis limited to oral mucosa associated with ulcerative colitisA case of acquired haemophilia A in a patient with bullous pemphigoid and review of the Japanese literatureSecukinumab decreases serum Krebs von den Lungen 6 (KL-6) level in patients with psoriasis with elevated serum KL-6 levelEfficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature ReviewUsefulness of real-time elastography for diagnosing lymph node metastasis of skin cancer: does elastography potentially eliminate the need for sentinel lymph node biopsy in squamous cell carcinoma?Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumabSerum infliximab level in an infant delivered from a mother with psoriatic arthritis receiving infliximabSecukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoidSuccessful treatment of palmoplantar pustular psoriasis with brodalumabThe vitamin D3 analog, maxacalcitol, reduces psoriasiform skin inflammation by inducing regulatory T cells and downregulating IL-23 and IL-17 productionAssessment of endothelial function during the loading phase of infliximab in psoriasis: a potential predictor of its drug survivalCalcipotriol and betamethasone dipropionate exhibit different immunomodulatory effects on imiquimod-induced murine psoriasiform dermatitisThyroid dysfunction in patients with psoriasis: Higher prevalence of thyroid dysfunction in patients with generalized pustular psoriasisCase of generalized pustular psoriasis with coexisting mutations in IL36RN and CARD14A case of type 1 segmental Darier disease showing widespread Blaschkoid skin lesions with p.P160L mutation in ATP2A2Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective studyAnti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitisConjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world settingScalp psoriasis in a haemodialysis patient successfully treated with a half-dose of apremilastDupilumab Improved Alopecia Areata in a Patient with Atopic Dermatitis: A Case ReportLong-term Use of Topical Bimatoprost on Rhododendrol-induced Refractory Leukoderma: A Case ReportGastrointestinal bleeding with severe mucosal involvement in a patient with generalized pustular psoriasis without IL36RN mutationHigher baseline serum lactate dehydrogenase level is associated with poor effectiveness of dupilumab in the long term in patients with atopic dermatitis
P50
Q40738483-B2B6F34F-256D-465D-9C21-A6AB327D8C5BQ48092133-F0CE5896-CE94-4360-A8A5-3F9A0F9C68F5Q48144965-E35A2C49-B0FF-44C1-AC2C-CA9D484E4CF0Q50045783-4C546807-843F-474D-B377-C8B45E552D1EQ64987456-B335CE5C-92D1-45F7-99A3-814F92E7C4CDQ87945757-BE82A0E4-62C5-4526-A067-59ADBA5B7664Q88359311-DEE0C33E-7B14-4D26-8369-7AC720750C32Q89306598-5DFAF846-4A1E-4317-8AC4-442D2B45D11DQ89473134-0C247569-5C5A-47D9-861A-2B5F24849A13Q89978216-465872F0-EBAD-4809-AF60-C8FCA82256EFQ90104370-3DCCA76A-2B15-4208-B5AB-F9092F054EAEQ90331293-1121A1EF-6004-495E-9DF7-B2EB421EFF0AQ90763234-41F4E2E0-856F-4548-ADE9-621AD7B196F9Q90976295-51E1B47E-233B-4AC7-92F6-3F760F2E53C3Q91059511-EBC7DED0-477C-4A1D-9D49-39823A1113AEQ91237023-6EEBA514-BD5F-4DE9-8D71-4C17943AE673Q91247587-6600B7E0-9F0C-477E-A78E-9E349FBC97FEQ91423869-4892DD4C-FF6C-4EFE-8985-3CF94484A779Q91713805-63952E24-ACE4-45F5-A526-8EA7BEB86A26Q91813154-45FF5964-A626-425D-8B91-41BF50609C5DQ92084376-757A3907-97AB-497D-A23B-967B3C9AF867Q92286640-84B30785-0F34-498A-97E0-872F90E9BD65Q92294351-E7D84B1B-1853-4735-B46D-6F66F13FBD77Q92298319-6E9B128B-F483-473C-96CC-56A483D7D216Q92472411-B73F3D9A-4FB5-43E6-9F99-C47B9A4DF51BQ92784513-151B97D5-776E-4C76-A1FD-D9A07FAF0090Q92865830-594CD67C-782E-46C2-8816-43BE7514383AQ93362764-365C15B8-226C-4A24-9883-D6B9CBD6917AQ96437408-910B4FA0-0543-4613-808D-15C946BD2007
P50
description
researcher
@en
name
Masahiro Kamata
@en
type
label
Masahiro Kamata
@en
prefLabel
Masahiro Kamata
@en
P31
P496
0000-0003-0976-4982